link ae888

Singaporean company helps Vietnam with rare disease treatment

Shire Singapore PTE. Ltd. (Shire) will help Vietnam improve the quality of diagnosis, treatment and management of a number of rare diseases in the country for the 2018-2023 period.
Singaporean company helps Vietnam with rare disease treatment ảnh 1At the signing ceremony (Photo: VNA)

Hanoi (VNA) – Shire Singapore PTE. Ltd. (Shire)will help Vietnam improve the quality of diagnosis, treatment and management ofa number of rare diseases in the country for the 2018-2023 period.

A memorandum of understanding (MoU) to this effect was signed byrepresentatives of the Medical Services Administration under Vietnam’s HealthMinistry and Shire Vietnam in Hanoi on April 20.

Under the MoU, the Singaporean company will also support Vietnam in improvingprofessional knowledge, implementing policies on rare disease management andensuring policies on rare medicine supply in the country, said Luong Ngoc Khue,Director of the Medical Services Administration.

During the first stage, the two sides will work together to develop a nationalguideline to improve the quality of diagnosis, treatment and management ofHaemophilia and Primary Immune Deficiency (PID) as well as to support policydevelopment on rare diseases in Vietnam.

Linda Seah, head of Southeast Asia Cluster at Shire, said Haemophilia and PIDare complex rare disorders that require continuous medical research andinnovative approach to ensure positive outcome for patients.

The MoU is the first of its kind for Shire in Asia Pacific, aiming not only toshorten the time for diagnosis but also ensure that patients are well supportedwith adequate access to therapy and management over the course of their life-longconditions, she said.

According to the World Health Organisation (WHO), there are approximately 100rare diseases reported in Vietnam. It is estimated that almost one in 15persons, or approximately six million people in the country, suffer from a raredisease. Vietnam has more than 6,000 haemophilia patients, but only 2,400 havebeen detected their disease situation, while PID remains common and adverselyaffects the prognosis of these patients. –VNA 
VNA

See more

Assoc. Prof. Dr Nguyen Viet Nhung, Dean of Medicine at University of Medicine and Pharmacy, Vietnam National University (VNU) Hanoi, speaks online on Vietnam’s digital transformation strategy in medical education. (Photo: VNA)

🐟 Forum spotlights AI and digital innovation in healthcare

To achieve its goal of becoming a developed nation by 2045, Vietnam is prioritising the integration of AI and digital tools into the training of future doctors, said Assoc. Prof. Dr. Nguyen Viet Nhung, Dean of Medicine at University of Medicine and Pharmacy, Vietnam National University (VNU) Hanoi.
A banner on the side of a car urges people to quit smoking for their own health and that of their loved ones (Photo: VNA)

♒ Sharp tobacco tax hike urged to safeguard youths, community health

A 2023 report by the Vietnam Health Economics Association estimated that the total cost of tobacco-related healthcare and economic losses reached 108 trillion VND (4.14 billion USD) annually – equivalent to 1.14% of GDP and five times higher than the budget revenue generated by the tobacco industry.
On the morning of May 26, 2025, following bilateral talks at the Presidential Palace, President Luong Cuong (first, right) and French President Emmanuel Macron (first, left) witness the exchange of cooperation documents between leaders of ministries, agencies, and enterprises from both countries. In the photo: Ngo Chi Dung, General Director and Chairman of the Board of Viet Nam Vaccine Company (VNVC) (second, right), and Zainab Sadat Qayyum, President of Sanofi Southeast Asia – India, exchange the cooperation agreement on the transfer of Sanofi’s vaccine production technology to VNVC’s vaccine and biologicals plant. (Photo: VNVC)

💟 Vietnam, France collaborate in vaccine production technology transfer

Under the agreement, VNVC and Sanofi will gradually implement technology transfers to enable domestic production of several key Sanofi vaccines that are widely used in Vietnam. In addition, Sanofi will support VNVC in training human resources and quality management in vaccine research and manufacturing.
{dagathomo tructiep hôm nay}|{link link link ae888}|{dá gà thomo}|{trực tiếp đá gà thomo hom nay}|{sbobet asian handicap}|